Plasma levels of catecholamines and asymmetric dimethylarginine levels as predictive values of mortality among hemodialysis patients

Marcin Dziedzic; Ewelina Orlowska; Kinga Gawel; Magdalena Zawadzka; Anna Bednarek-Skublewska; Janusz Solski

doi:10.2478/cipms-2014-0010

.blurhash-client-img { display: none !important; }

Plasma levels of catecholamines and asymmetric dimethylarginine levels as predictive values of mortality among hemodialysis patients

Current Issues in Pharmacy and Medical Sciences

Volume 27 (2014): Issue 1 (June 2014)

By: Marcin Dziedzic, Ewelina Orlowska, Kinga Gawel, Magdalena Zawadzka, Anna Bednarek-Skublewska and Janusz Solski

Open Access

|May 2014

Read online

Abstract

The aim of the study was to assess plasma concentration of catecholamines and asymmetric dimethyl arginine levels and a possible relationship to predict the mortality rates among hemodialysis patients. The study population comprised 27 subjects, aged 65-70 years. Each patient underwent dialysis thrice a week. Furthermore, the median duration of hemodialysis was 3.5 years. Based on the conducted research, it can be concluded that the concentrations of adrenaline and the level of asymmetric dimethylarginine have predictive value of mortality among hemodialysis patients. Of note, lowering plasma asymmetric dimethylarginine concentration may represent therapeutic target for prevention of progressive renal damage.

References

1. Agarwal R. et al.: Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am. J. Med., 115, 291, 2003.
Search in Google Scholar
2. Aldamiz-Echevarria L., Andrade F.: Asymmetric dimethylarginine, endothelial dysfunction and renal disease. Int. J. Mol. Sci.,13, 11288, 2012.
Search in Google Scholar
3. Alsagaff M.Y. et al.: Asymmetric dimethylarginine: a novel cardiovascular risk factor in end-stage renal disease. J. Int. Med. Res., 40, 340, 2012.10.1177/14732300120400013522429374
Open DOI Search in Google Scholar Open in PubMed
4. Arici M., Walls J.: End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? Kidney Int., 59, 407, 2001.
Search in Google Scholar
5. Bassareo P.P. et al.: Urinary NGAL and hematic ADMA levels: an early sign of cardio-renal syndrome in young adults born preterm? J. Matern. Fetal Neonatal Med., 26, 80, 2013.10.3109/14767058.2013.82969824059560
Open DOI Search in Google Scholar Open in PubMed
6. Bassareo P.P. et al.: Could ADMA levels in young adults born preterm predict an early endothelial dysfunction? Int. J. Cardiol., 159, 217, 2012.10.1016/j.ijcard.2011.02.06921420186
Open DOI Search in Google Scholar Open in PubMed
7. De Jager D.J. et al.: Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA, 302, 1782, 2009.10.1001/jama.2009.148819861670
Open DOI Search in Google Scholar Open in PubMed
8. Goonasekera C.D. et al.: Nitric oxide synthase inhibitors and hypertension in children and adolescents. J. Hypertens., 15, 901, 1997.10.1097/00004872-199715080-000159280214
Open DOI Search in Google Scholar Open in PubMed
9. Guerin A, Pannier B, London G.: Atherosclerosis versus arterial stiffness in advanced renal failure. Adv. Cardiol.,44, 187, 2007.
Search in Google Scholar
10. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis., 39, 1, 2002.
Search in Google Scholar
11. Kielstein J.T. et al.: Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J. Am. Soc.Nephrol., 13, 170, 2002.10.1681/ASN.V13117011752034
Open DOI Search in Google Scholar Open in PubMed
12. Kielstein J.T. et al.: Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J. Am. Soc. Nephrol., 10, 594, 1999.10.1681/ASN.V10359410073610
Open DOI Search in Google Scholar Open in PubMed
13. Kielstein J.T. et al.: Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. Kidney Blood Press. Res., 27, 143, 2004.10.1159/00007883815192321
Open DOI Search in Google Scholar Open in PubMed
14. Koch M. et al.: Relevance of conventional cardiovascular risk factors for the prediction of coronary artery disease in diabetic patients on renal replacement therapy. Nephrol. Dial. Transplant., 12, 1187, 1997.10.1093/ndt/12.6.11879198049
Open DOI Search in Google Scholar Open in PubMed
15. Luyckx V.A., Brenner B.M. Low birth weight, nephron number and kidney disease. Kidney Int., 97, 68, 2005.
Search in Google Scholar
16. Mallamaci F. et al.: Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J. Am. Soc. Nephrol., 15, 435, 2004.10.1097/01.ASN.0000106717.58091.F6
Open DOI Search in Google Scholar
17. Nakayama Y. et al.: Asymmetric dimethylarginine accumulates in the kidney during ischemia/reperfusion injury. Kidney Int., 9, 1, 2013.
Search in Google Scholar
18. Perticone F. et al.: Endothelial dysfunction, ADMA and insulin resistance in essential hypertension. Int. J. Cardiol., 142, 236, 2010.
Search in Google Scholar
19. Raptis V., Kapoulas S., Grekas D.: Role of asymmetrical dimethylarginine in the progression of renal disease. Nephrology (Carlton), 18, 11, 2013.
Search in Google Scholar
20. Rocha M.S. et al.: Asymmetric dimethylarginine in adults with cystathionine β-synthase deficiency. Atherosclerosis, 222, 509, 2012.10.1016/j.atherosclerosis.2012.03.00922484094
Open DOI Search in Google Scholar Open in PubMed
21. Rodriguez M.M. et al.: Comparative renal histomorphometry: a case study of oligonephropathy of prematurity. Pediatr. Nephrol., 20, 945, 2005.10.1007/s00467-004-1800-x15856326
Open DOI Search in Google Scholar Open in PubMed
22. Rutkowski B. et al.: Raport o stanie leczenia nerkozastępczego w Polsce 2009. Drukonsul, Gdańsk 2010.
Search in Google Scholar
23. Sarnak M.J., Levey A.S.: Epidemiology, diagnosis, and management of cardiac disease in chronic renal disease. J. Thromb. Thrombolysis, 10, 169, 2000.
Search in Google Scholar
24. Schwarz P. et al.: Endogenous and exogenous nitric oxide inhibits norepinephrine release from rat heart sympathetic nerves. Circ. Res., 77, 841, 1995.10.1161/01.RES.77.4.8417554131
Open DOI Search in Google Scholar Open in PubMed
25. Sesti G. et al.: A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with chronic kidney disease.Atherosclerosis, 231, 141, 2013.10.1016/j.atherosclerosis.2013.08.04124125425
Open DOI Search in Google Scholar Open in PubMed
26. Sibal L. et al.: The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr. Cardiol.Rev., 6, 82, 2010.10.2174/157340310791162659289208021532773
Open DOI Search in Google Scholar Open in PubMed
27. Sydow K. et al.: Distribution of asymmetric dimethylarginine among 980 healthy, older adults of different ethnicities. Clin. Chem., 56, 111, 2010.10.1373/clinchem.2009.13620019892843
Open DOI Search in Google Scholar Open in PubMed
28. Tripepi G. et al.: Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients.Clin. J. Am. Soc. Nephrol., 6, 1714, 2011.10.2215/CJN.1129121021642364
Open DOI Search in Google Scholar Open in PubMed
29. U.S. Renal Data System, USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2013.
Search in Google Scholar
30. Ueda S. et al.: Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease. Nephrology, 12, 582, 2007.10.1111/j.1440-1797.2007.00840.x17995585
Open DOI Search in Google Scholar Open in PubMed
31. Wilcken D.E. et al.: Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of l-arginine on its metabolism. Mol. Genet. Metab., 91, 309, 2007.10.1016/j.ymgme.2007.04.01717560156
Open DOI Search in Google Scholar Open in PubMed
32. Zoccali C. et al.: Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J. Am.Soc. Nephrol., 13, 490, 2002.
Search in Google Scholar
33. Zoccali C. et al:. Inflammation is associated with carotid atherosclerosis in dialysis patients. J. Hypertens., 18, 1207, 2000.10.1097/00004872-200018090-0000610994751
Open DOI Search in Google Scholar Open in PubMed

Articles in this issue

DOI: https://doi.org/10.2478/cipms-2014-0010 | Journal eISSN: 2300-6676 | Journal ISSN: 2084-980X

Journal RSS Feed

Language: English

Page range: 37 - 40

Submitted on: Feb 13, 2014

Accepted on: Mar 6, 2014

Published online: May 30, 2014

Published in print: Jun 1, 2014

Published by: Sciendo

In partnership with: Paradigm Publishing Services

Keywords:

catecholamines,

asymmetric dimethylarginine,

Related subjects:

Pharmacology, toxicology

© 2014 Marcin Dziedzic, Ewelina Orlowska, Kinga Gawel, Magdalena Zawadzka, Anna Bednarek-Skublewska, Janusz Solski, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 27 (2014): Issue 1 (June 2014)